Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth

Obesity and diabetes are associated with worse prognosis for numerous malignancies. Both insulin resistance and altered levels of adipokines may explain the link between obesity and tumor progression. In preclinical models, METAP2 inhibitors induce weight loss and possess anti-tumor activity, but th...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Peter Cornelius, Benjamin A. Mayes, Andrew J. Dannenberg, Pierre J. Dufour, Sara Little, Douglas V. Guzior, John S. Petersen, James M. Shanahan, Bradley J. Carver
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2026-02-01
Sarja:	Frontiers in Oncology
Aiheet:	adiponectin insulin leptin metabo-oncology METAP2 obesity
Linkit:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1751681/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!